Immunic reports $43.4M Q3 costs ahead of December MS trial data

Image
Immunic reports $43.4M Q3 costs ahead of December MS trial data

NEW YORK – November 13, 2026 -- Immunic, Inc. (Nasdaq: IMUX) says top-line data from its two Phase 3 ENSURE trials of vidofludimus calcium in relapsing

Published by:
fairsonline_team
Industries